Alba Erra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alba Erra has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Silvia Martínez Pardo
Hospital Universitari Mútua Terrassa Rheumatology Department Terrassa
3 shared publications - Ana Monegal
Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Spain
2 shared publications - Carmen Gómez-Vaquero
Department of Rheumatology, IDIBELL-Hospital Universitari de Bellvitge, University of Barcelona, 08907 Barcelona, Spain
2 shared publications - Concepción Pittarch
Hospital Esperit Sant, Spain
2 shared publications - Dacia Cerdà
Unidad de Reumatología, Servicio de Medicina Interna, Hospital General de Granollers, Barcelona, España
2 shared publications - Dolors Boquet
Hospital Arnau de Vilanova, Spain
2 shared publications
Latest Publications
- 1 December 2017
- Published by Elsevier in Clinica Chimica Acta
- Vol. 475, 169-171
Concordance between direct and indirect measurements of free 25-OH vitamin D
- 1 December 2017
- Published by Elsevier in Clinica Chimica Acta
- Vol. 475, 169-171
Concordance between direct and indirect measurements of free 25-OH vitamin D
- 2 May 2017
- Published by Springer Nature in Osteoporosis International
- Vol. 28 (8) , 2457-2464
Comparison of total, free and bioavailable 25-OH vitamin D determinations to evaluate its biological activity in healthy adults: the LabOscat study
Summary Determination of different forms of 25-OHD (total, free and bioavailable) in healthy young women does not offer additional advantages over standard 25-OHDT for evaluating vitamin D deficiency. In these subjects 25-OHDT values T), DBP, albumin, PTH and bone formation (PINP,OC) and resorption (NTx,CTx) markers. Free(25-OHDF) and bioavailable (25-OHDB) serum 25-OHD levels were estimated by DBP and albumin determinations and also directly by ELISA (25-OHDF-2). We analysed threshold PTH values for the different forms of 25-OHD and the correlations and differences according to 25-OHDT levels T (15.4 ± 1.4 vs. 18.3 ± 2.7, p < 0.05) and 25OHDB values (1.7 ± 0.2 vs. 2.2 ± 0.09, p < 0.05). The different forms of 25OHD were significantly intercorrelated, with marginal correlations between PTH and 25-OHDT (r = −0.136, p = 0.082). Conclusions Determination of different forms of 25-OHD in healthy young women does not offer additional advantages over standard 25-OHDT for evaluating vitamin D deficiency. In these subjects 25-OHDT values <15 ng/ml would be more appropriate for defining this deficiency.
- 2 May 2017
- Published by Springer Nature in Osteoporosis International
- Vol. 28 (8) , 2457-2464
Comparison of total, free and bioavailable 25-OH vitamin D determinations to evaluate its biological activity in healthy adults: the LabOscat study
Summary Determination of different forms of 25-OHD (total, free and bioavailable) in healthy young women does not offer additional advantages over standard 25-OHDT for evaluating vitamin D deficiency. In these subjects 25-OHDT values T), DBP, albumin, PTH and bone formation (PINP,OC) and resorption (NTx,CTx) markers. Free(25-OHDF) and bioavailable (25-OHDB) serum 25-OHD levels were estimated by DBP and albumin determinations and also directly by ELISA (25-OHDF-2). We analysed threshold PTH values for the different forms of 25-OHD and the correlations and differences according to 25-OHDT levels T (15.4 ± 1.4 vs. 18.3 ± 2.7, p < 0.05) and 25OHDB values (1.7 ± 0.2 vs. 2.2 ± 0.09, p < 0.05). The different forms of 25OHD were significantly intercorrelated, with marginal correlations between PTH and 25-OHDT (r = −0.136, p = 0.082). Conclusions Determination of different forms of 25-OHD in healthy young women does not offer additional advantages over standard 25-OHDT for evaluating vitamin D deficiency. In these subjects 25-OHDT values <15 ng/ml would be more appropriate for defining this deficiency.
- 23 November 2015
- Published by Springer Nature in Rheumatology International
- Vol. 36 (3) , 365-369
Nailfold capillaroscopic findings in primary Sjögren’s syndrome with and without Raynaud’s phenomenon and/or positive anti-SSA/Ro and anti-SSB/La antibodies
The aim of this study was to assess nailfold capillaroscopic (NC) findings in patients with primary Sjögren’s syndrome (PSS) with and without Raynaud’s phenomenon (RP) as well as in the presence of positive anti-SSA/Ro and anti-SSB/La antibodies. Videocapillaroscopy was performed in 150 patients with PSS. Data collected included demographics, presence of RP, PSS symptoms, antinuclear antibodies, rheumatoid factor, anti-Ro, anti-La, anti-CCP, salivary scintigraphy, labial biopsy, and NC findings. RP was present in 32 % of PSS, keratoconjunctivitis sicca in 91 %, oral xerosis in 93 %, and skin or genital xerosis in 53 %. In patients with positive anti-SSA/Ro (75 %) and positive anti-SSB/La (40 %), NC showed normal findings in 53 % of cases and non-specific in 36 %. In patients with PSS, NC was normal in 51 % of cases and non-specific in 34 %. Scleroderma pattern was found in 14 patients. RP associated with PSS had non-specific capillaroscopy in 40 % of cases (p = 0.1). Pericapillary haemorrhages (p = 0.06) and capillary thrombosis (p = 0.2) were not increased, but more dilated capillaries were detected in 48 % of cases. Patients with positive anti-Ro and/or anti-La have not a distinct NC profile. Patients with RP associated with PSS had more dilated capillaries, but neither pericapillary haemorrhages nor capillary thrombosis was observed.
- 23 November 2015
- Published by Springer Nature in Rheumatology International
- Vol. 36 (3) , 365-369
Nailfold capillaroscopic findings in primary Sjögren’s syndrome with and without Raynaud’s phenomenon and/or positive anti-SSA/Ro and anti-SSB/La antibodies
The aim of this study was to assess nailfold capillaroscopic (NC) findings in patients with primary Sjögren’s syndrome (PSS) with and without Raynaud’s phenomenon (RP) as well as in the presence of positive anti-SSA/Ro and anti-SSB/La antibodies. Videocapillaroscopy was performed in 150 patients with PSS. Data collected included demographics, presence of RP, PSS symptoms, antinuclear antibodies, rheumatoid factor, anti-Ro, anti-La, anti-CCP, salivary scintigraphy, labial biopsy, and NC findings. RP was present in 32 % of PSS, keratoconjunctivitis sicca in 91 %, oral xerosis in 93 %, and skin or genital xerosis in 53 %. In patients with positive anti-SSA/Ro (75 %) and positive anti-SSB/La (40 %), NC showed normal findings in 53 % of cases and non-specific in 36 %. In patients with PSS, NC was normal in 51 % of cases and non-specific in 34 %. Scleroderma pattern was found in 14 patients. RP associated with PSS had non-specific capillaroscopy in 40 % of cases (p = 0.1). Pericapillary haemorrhages (p = 0.06) and capillary thrombosis (p = 0.2) were not increased, but more dilated capillaries were detected in 48 % of cases. Patients with positive anti-Ro and/or anti-La have not a distinct NC profile. Patients with RP associated with PSS had more dilated capillaries, but neither pericapillary haemorrhages nor capillary thrombosis was observed.
- Open Access
- 4 September 2015
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 17 (1) , 242
Variation at interleukin-6 receptor gene is associated to joint damage in rheumatoid arthritis
Interleukin-6 (IL-6) cytokine signaling is key in Rheumatoid Arthritis (RA) pathophysiology. Blocking IL-6 receptor (IL6R) has proven to be a highly effective treatment to prevent joint damage. This study was performed to investigate the association between the genetic variation at IL6R gene and the severity of joint damage in RA. IL6R gene tagging SNPs (n = 5) were genotyped in a discovery group of 527 RA patients from 5 different university hospitals from Spain. For each marker, a linear regression analysis was performed using an additive model and adjusting for the years of evolution of the disease, autoantibody status, gender and age. Haplotypes combining the SNPs were also estimated and tested for association with the level of joint destruction. Using an independent cohort of 705 RA patients from 6 university hospitals we performed a validation study of the SNPs associated in the discovery phase. In the discovery group we found a highly significant association between IL6R SNP rs4845618 and the level of joint destruction in RA (P = 0.0058, P corrected = 0.026), and a moderate association with SNP rs4453032 (P = 0.02, P corrected = 0.05). The resulting haplotype from both SNPs was more significantly associated with joint damage (P = 0.0037, P corrected = 0.011). Using the validation cohort, we replicated the association between the two IL-6R SNPs with the degree of joint destruction in RA (P = 0.007 and P = 0.04, meta-analysis P = 0.00011 and P = 0.0021, respectively), and the haplotype association (P = 0.0058, meta-analysis P = 6.64 e-5). Genetic variation at IL6R gene is associated with joint damage in RA.
- 4 September 2015
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 17 (1) , 242
Open AccessVariation at interleukin-6 receptor gene is associated to joint damage in rheumatoid arthritis
Interleukin-6 (IL-6) cytokine signaling is key in Rheumatoid Arthritis (RA) pathophysiology. Blocking IL-6 receptor (IL6R) has proven to be a highly effective treatment to prevent joint damage. This study was performed to investigate the association between the genetic variation at IL6R gene and the severity of joint damage in RA. IL6R gene tagging SNPs (n = 5) were genotyped in a discovery group of 527 RA patients from 5 different university hospitals from Spain. For each marker, a linear regression analysis was performed using an additive model and adjusting for the years of evolution of the disease, autoantibody status, gender and age. Haplotypes combining the SNPs were also estimated and tested for association with the level of joint destruction. Using an independent cohort of 705 RA patients from 6 university hospitals we performed a validation study of the SNPs associated in the discovery phase. In the discovery group we found a highly significant association between IL6R SNP rs4845618 and the level of joint destruction in RA (P = 0.0058, P corrected = 0.026), and a moderate association with SNP rs4453032 (P = 0.02, P corrected = 0.05). The resulting haplotype from both SNPs was more significantly associated with joint damage (P = 0.0037, P corrected = 0.011). Using the validation cohort, we replicated the association between the two IL-6R SNPs with the degree of joint destruction in RA (P = 0.007 and P = 0.04, meta-analysis P = 0.00011 and P = 0.0021, respectively), and the haplotype association (P = 0.0058, meta-analysis P = 6.64 e-5). Genetic variation at IL6R gene is associated with joint damage in RA.
- Open Access
- 31 March 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (9) , 1123-1124
Is the recommended dose of leflunomide the best regimen to treat rheumatoid arthritis patients?
Sir, The aim of this letter is to show our experience in the use of leflunomide (LFN) and express our opinion about the recommended dose [1, 2]. As far as we know, no data exist about a possible association between the loading dose and the presence of adverse events. Any new suggestion about the use of LFN should be appreciated, specially after the safety of this drug has been questioned.
- 31 March 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (9) , 1123-1124
Open AccessIs the recommended dose of leflunomide the best regimen to treat rheumatoid arthritis patients?
Sir, The aim of this letter is to show our experience in the use of leflunomide (LFN) and express our opinion about the recommended dose [1, 2]. As far as we know, no data exist about a possible association between the loading dose and the presence of adverse events. Any new suggestion about the use of LFN should be appreciated, specially after the safety of this drug has been questioned.